Moreshwar Pandharinath Patil

Moreshwar Pandharinath Patil

Auto-generated profile, based on publicly available information

Moreshwar Pandharinath Patil

MET’s Institute of Pharmacy, Bhujbal Knowledge City, Adgaon, Nashik, (affiliated to Savitribai Phule Pune University, Pune), Maharashtra 422 003, India

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2013 in Drug Delivery
Verified
Journal Article
Closed access
KNKishor V. Nikumbh
Kishor V. Nikumbh
SSShailesh G. Sevankar
Shailesh G. Sevankar
MPMoreshwar P. Patil
Moreshwar P. Patil
Anti-inflammatory agents are widely used to relieve inflammation caused by various factors. This study was initiated with the intention to deliver low aqueous soluble ketoprofen to enhance its solubility by developing microemulsion system as a template and then incorporating it into gel phase. Initially ketoprofen was solubilized into microemulsion preparation made up of clove oil, Tween 20 and propylene glycol as oil phase, surfactant and co-surfactant respectively, then it was incorporated into different concentration of gelling phase using gelling agents namely Carbopol 940, Carbopol 934 and hydroxypropyl methyl cellulose K(4)M (HPMC K(4)M). Formulated emulgels were evaluated for their physical appearance, pH, rheological properties, globule size, extrudability, drug content, spreadability, bioadhesion strength, in vitro and ex vivo drug release, skin irritation test and anti-inflammatory activity. Microemulsion had shown globule size 396 nm, pH 6-6.7, viscosity 29.4 cps and zeta potential -12 mV indicating good stability. Formulated emulgels showed good physical appearance, skin acceptable pH 6-6.9, non-Newtonian shear thinning system, drug content 99.28 ± 0.16%, bioadhesion strength 48.4 gram force, globule size 473 nm, spreadability 22.96 gm.cm/s, good extrudability, in vitro release, ex vivo release did not showed any irritation reaction and possess a good anti-inflammatory activity. Selected batch showed enhanced drug release (92.42 ± 4.66%) as compared to marketed gel (65.94 ± 3.30). Similarly ex vivo release of formulation showed 72.22% release through mice skin compared with marketed gel. Formulations followed Korsmeyer-Peppas diffusion kinetic model. It was observed from the results that the formulated emulgel can provide promising delivery of ketoprofen.

19 September 2016 in Journal of Pharmaceutical Investigation
Verified
Journal Article
Closed access
PDF file
DPDurgesh Rameshlal Parakh
Durgesh Rameshlal Parakh
MPMoreshwar Pandharinath Patil
Moreshwar Pandharinath Patil
SSSandeep Suresh Sonawane
Sandeep Suresh Sonawane
SKSanjay Jayprakash Kshirsagar
Sanjay Jayprakash Kshirsagar

31 May 2016 in Drying Technology
Verified
Journal Article
Closed access
DPDurgesh Rameshlal Parakh
Durgesh Rameshlal Parakh
MPMoreshwar Pandharinath Patil
Moreshwar Pandharinath Patil
NDNeelam Laxman Dashputre
Neelam Laxman Dashputre
SKSanjay Jayprakash Kshirsagar
Sanjay Jayprakash Kshirsagar
In this study, a novel liquid self-microemulsifying drug delivery system (SMEDDS) containing mebendazole was formulated and further developed into a solid form by a spray drying method using Aerosil 200 as the solid carrier. The optimum liquid SMEDDS consisted of Labrafil 2125 CS, Tween 20, and Maisine 35-1 as the oil phase, the surfactant, and the cosurfactant, respectively. The formulated SMEDDS was completely emulsified or dispersed within a minute. All formulations were dissolved within 1 h using 0.1 N HCl as dissolution medium, whereas pure drug was less significantly dissolved in this time period. The droplet size was found to be within 250 nm for solid forms of SMEDDS. Solid state characterization was performed by scanning electron micrograph, differential scanning calorimetry, and X-ray powder diffraction. After oral administration to Wistar rats, mebendazole in the solid SMEDDS resulted in the significant improvement in bioavailability compared with that of pure drug analyzed by RP-HPLC. The optimized formulation showed 24.87 folds increase in bioavailability as compared to pure drug and 8.39 folds increase in bioavailability in comparison to marketed tablet of mebendazole. The optimized batch has found to be 3.1726 years of shelf life. In conclusion, the solid SMEDDS is a promising solid dosage form for poorly water-soluble and low bioavailability drugs.

1 May 2015 in Drying Technology
Verified
Journal Article
Closed access
SDSnehlata Dasharath Dharankar
Snehlata Dasharath Dharankar
DPDurgesh Rameshlal Parakh
Durgesh Rameshlal Parakh
MPMoreshwar Pandharinath Patil
Moreshwar Pandharinath Patil
SKSanjay Jayprakash Kshirsagar
Sanjay Jayprakash Kshirsagar

20 June 2021 in Ars Pharmaceutica (Internet)
Verified
Journal Article
Open access
PDF file
MPMoreshwar Patil
Moreshwar Patil
PPPrashant Pandit
Prashant Pandit
PUPavan Bhausaheb Udavant
Pavan Bhausaheb Udavant
SSSandeep Sonawane
Sandeep Sonawane
DBDeepak Bhambere
Deepak Bhambere
Introducción: Etodolac se usa en el tratamiento del dolor agudo y la inflamación. Tiene baja solubilidad debido a la alta hidrofobia y se informa que tras la administración oral muestra alteraciones gástricas. Esto fomenta el desarrollo de formulación tópica en lugar de oral. Método: En este trabajo utilizamos el método de separación de fase de coacervación para el desarrollo del sistema vesicular cargado con etodolaco mediante el uso de tensioactivos no iónicos, colesterol y lecitina de soja. El diseño central compuesto (rotativo) se utilizó para optimizar las concentraciones de lecitina de soja, surfactante y colesterol. Las formulaciones preparadas se caracterizaron por análisis de tamaño de vesículas, potencial zeta, eficiencia de atrapamiento, permeación in vitro, permeación ex vivo y estudio antiinflamatorio. Resultados: Etodolac quedó atrapado con éxito en todas las formulaciones que tenían una eficiencia en el intervalo de 74,36% a 90,85%, siendo mayor a 4 ° C que a temperatura ambiente. Cuando se hidrata con agua, los niosomas se producen espontaneamente el rango de 54 a 141 (por mm cúbico). Los resultados del estudio de difusión in vitro revelaron que el etodolaco se liberó en un rango de 71,86 a 97,16% durante un período de 24 horas. El tamaño medio de vesícula de la formulación optimizada se encontró en 211,9 nm con un PDI de 0,5. Las respuestas observadas, es decir,% de eficacia de encapsulación y liberación de fármaco, fueron 74,12 y 95,08 respectivamente. El potencial zeta fue de -19,4 mV y reveló la estabilidad de la formulación, que fue confirmada adicionalmente por la ausencia de cambios en el contenido del fármaco y la liberación del fármaco después de los estudios de estabilidad. El% de inhibición en el volumen de la pata fue del 40,52% y del 43,61% para la prueba y el gel proniosómico comercializado. Conclusión: la formulación de gel proniosomal fue estable y podría mejorar el suministro de etodolaco a la piel debido a la excelente capacidad de permeación del sistema vesicular.

1 January 2013 in Asian Journal of Pharmaceutics
Verified
Journal Article
Open access
PDF file
JJJitendra Jagtap
Jitendra Jagtap
MPMoreshwar Patil
Moreshwar Patil
VPVijay Patil
Vijay Patil
The delivery of drugs to the colon through oral route is valuable in treating diseases of the colon with the expectation to protect the drug during the transit time in the gastrointestinal tract and to allow its release only in the colon. The objective of this study was to develop colon targeted drug delivery system for satranidazole that is used in the treatment of amoebiasis. Matrix tablets containing a combination of guar gum and hydroxypropyl methyl cellulose (HPMC) K4M in different ratios were prepared by wet granulation technique followed by enteric coating with Eudragit S100. Citric acid was also added, which might further facilitate drug dissolution and absorption. All formulations were evaluated for hardness, swelling, drug content and in-vitro drug release studies. The results of the studies showed that colon targeted matrix tablet of satranidazole containing guar gum and HPMC K4M in the ratio proportion of 3:1 does not released drug in 0.1N HCl (pH 1.2) and small intestine (phosphate buffer, pH 7.4). When the dissolution study was continued in colonic fluids (phosphate buffer, pH 6.8), the matrix tablets released 79.21% drug while in the presence of 4% rat cecal content, it was 94.08% at the end of the 24 h. It was expected that guar gum could be degraded by colonic microflora containing anaerobic microorganism and the release may be controlled by HPMC K4M and citric acid. Studies demonstrated that orally administered Satranidazole matrix tablets can be used effectively for the delivery of the drug to the colon.